Clene Nanomedicine, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2013-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.clene.com
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
Phase 2
Terminated
- Conditions
- Relapsing Remitting Multiple SclerosisOptic NeuropathyOptic; Neuritis, With Demyelination
- Interventions
- Drug: PlaceboDrug: CNM-Au8
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Clene Nanomedicine
- Target Recruit Count
- 73
- Registration Number
- NCT03536559
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇦🇺John Hunter Hospital, New Lambton Heights, New South Wales, Australia
🇦🇺Sydney Brain Mind Centre, Sydney, New South Wales, Australia
A Phase I SAD and MAD Clinical Trial of CNM-Au8 in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers - Male and Female
- Interventions
- Other: PlaceboOther: CNM-Au8
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Clene Nanomedicine
- Target Recruit Count
- 86
- Registration Number
- NCT02755870
- Locations
- 🇳🇱
Centre for Human Drug Research (CHDR), Leiden, Netherlands
© Copyright 2025. All Rights Reserved by MedPath